Share
149 Posts.
lightbulb Created with Sketch. 40
clock Created with Sketch. 27/02/24
11:49
Share
Originally posted by Atomboi:
↑
There is a chance to go to $18 but the reality is we are unlikely to be in this alone once positive results come through - therefore making that a dream scenario.If positive results come through we can go down two main routes: 1. pPRV $100m funds us moving into the 25-27CY period - If we gain the Pediatric Priority Review Voucher (pPRV) and sell it at $100m - PER could self fund the next stages in CY2025-2027 without the need to capital raise (and therefore dilute more). We partner - PER will be almost guaranteed a move the drug to market. However, over 50% of the company will be owned by the partner. Meaning control of the company. The deal would likely provide an upfront payment and HOPEFULLY on-going royalties. The latest presentation from PER has outlined three possible scenarios.If we partner the key for me if CEO would be to only sell the rights to use in DMD and PER continues to own the rights to use in other inflammation based areas. INFLAMMATION is the base of so much - and this is the dream area - where our SP could FLY! So when we are really dreaming...
Expand
If I remember correctly, you are only given the PRV at marketing approval (during the NDA submission) which can be use/sell for the priority review of another drug. Not sure if it is given upon accelerated approval..
